Dr. Albert Baldwin, a Professor at the University of North Carolina at Chapel Hill, formed Theralogics in 2004 to provide a focused vehicle for the discovery and development of NF-B-related discoveries and technologies. He was joined in this effort by his longtime colleagues, Dr. Sankar Ghosh of Yale University and Dr. Sergei Makarov of the transcription factor profiling company Attagene, as well as by biotech entrepreneur and executive Max Wallace.

Theralogics, based in Chapel Hill, NC, has licensed key NF-B-related technologies from both UNC and Yale and has built a unique national network of scientific collaborators who are able to quickly test discoveries and technologies in a series of highly relevant models of disease. Using this model, Theralogics has already made important discoveries in several disease areas, most especially in recent collaborative work done with Dr. Denis Guttridge of the Ohio State University in the field of Muscular Dystrophy.